Drug Patents owned by Mylan Speciality Lp

1. List of Astepro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine
Nov, 2025

(2 years from now)

US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Nov, 2025

(2 years from now)

US8071073 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Jun, 2028

(5 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2008

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO before it's patent expiration?
More Information on Dosage

2. List of Dymista drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(4 months from now)

US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(4 months from now)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2023

(6 months from now)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Dec, 2023

(10 months from now)

US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2024

(1 year, 23 days from now)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2026

(3 years from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2026

(3 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: Treatment of seasonal allergic rhinitis; Treatment of allergic rhinitis, including seasonal allergic rhinitis; Allergic rhinitis; Treatment of symptoms of seasonal allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's patent expiration?
More Information on Dosage

3. List of Edluar drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Apr, 2027

(4 years from now)

US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Feb, 2031

(8 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of EDLUAR before it's patent expiration?
More Information on Dosage

4. List of Elestrin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7198801 MYLAN SPECIALITY LP Formulations for transdermal or transmucosal application
Jun, 2022

(7 months ago)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 15 December, 2006

Treatment: NA

Dosage: GEL, METERED;TRANSDERMAL

More Information on Dosage

5. List of Epi E Z Pen Jr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(2 years from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(2 years from now)

US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(2 years from now)

US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(2 years from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 22 December, 1987

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

How can I launch a generic of EPI E Z PEN JR before it's patent expiration?
More Information on Dosage

6. List of Rowasa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7645801 MYLAN SPECIALITY LP Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Jul, 2027

(4 years from now)

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 24 December, 1987

Treatment: NA

Dosage: ENEMA;RECTAL

More Information on Dosage

7. List of Tobi Podhaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421166 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside
Dec, 2022

(a month ago)

US7368102 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycosides
Dec, 2022

(a month ago)

US8715623 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside
Dec, 2022

(a month ago)

US7516741 MYLAN SPECIALITY LP Aerosolization apparatus with feedback mechanism
Jan, 2024

(11 months from now)

USRE47526 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Apr, 2024

(1 year, 2 months from now)

US8069851 MYLAN SPECIALITY LP Aeorosolization apparatus with air inlet shield
Sep, 2024

(1 year, 7 months from now)

US11484671 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2024

(1 year, 9 months from now)

US8664187 MYLAN SPECIALITY LP Methods of treatment of endobronchial infections
Jun, 2025

(2 years from now)

US7559325 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Oct, 2025

(2 years from now)

US8869794 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncturing member
Sep, 2028

(5 years from now)

US10207066 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2030

(7 years from now)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 22 March, 2013

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic